Skip to main content

Table 1 Inconsistent results observed at the DNA and RNA/protein levels in patients with exonic-breakpoint fusions

From: Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer

Case

Sex

Age

Diagnosis

DNA NGS

RNA NGS

FISH

IHC

Fusion

Other variants

Open reading frame disruption

 P1

M

50

ADC

EML4-ALK (exon 21: intron 19)

TP53 p.L194P

−

+

−

 P2

M

66

ADC

EML4-ALK (exon 21: intron 19)

None

−

+

−

 P3

M

66

ADC

LMNA-NTRK1 (exon 8: intron 11)

FGFR2 p.S799fs

−

N/A

−

 P4

M

62

ADC

FGFR1-NSD3 (exon 14: intron 19)

None

−

N/A

N/A

 P5

F

46

ADC

CD74-ROS1 (exon 7: exon 33)

CTNNB1 p.S45P

−

+

−

5’-5’ fusion

 P6

M

54

ADC

ADAMTS2-RET (intron 10: exon 3)

EML4-ALK

EML4-ALK

N/A

N/A

 P7

M

81

ADC

WNT2-MET (intron 2: exon 11)

TP53 p.H179R, RB1 p.K143fs

−

N/A

N/A

 P8

F

58

ADC

NAMPT-EGFR (intron 1: exon 17)

None

−

N/A

N/A

 P9

M

66

ADC

FGFR2-FAM170B-AS1 (intron 17: exon 1)

TP53 p.R337C

−

N/A

N/A

3’-3’ fusion

 P10

F

76

ADC

NKAIN2-ROS1 (intron 6: exon 35)

None

−

N/A

−

 P11

F

67

ADC

ZDHHC17-ALK (intron 1: exon 2)

EGFR p.E709_T710>D

−

N/A

−

  1. F Female, M Male, ADC Adenocarcinoma, N/A Not available, NGS Next-generation sequencing, FISH Fluorescence in situ hybridization, IHC Immunohistochemistry, − negative, + positive